Phaseline

Companies › Checkpoint Therapeutics

Checkpoint Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 1, 1 Phase 4; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Cosibelimab (CK-301)
Programmed cell death 1 ligand 1 inhibitor
CD274Phase 1Lung Neoplasms; Cutaneous Squamous Cell Carcinoma–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03212404Cosibelimab (CK-301)Phase 1Lung NeoplasmsOncologyNov 2021
NCT07426484Cosibelimab (CK-301)Phase 4Cutaneous Squamous Cell CarcinomaOncologyDec 2030

From the company's SEC filings

Complete response letters from FDA

Private offerings reported to the SEC (Form D)

Targets

CD274 (1)

Companies with the same targets

AstraZeneca Pfizer IO Biotech ImmuneOncia Therapeutics Akeso Roche Biotheus Suzhou Suncadia Biopharmaceuticals Shine-On Biomedical 3D Medicines (Sichuan)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.